Along with its financial results for the second quarter of 2025, Merck revealed a restructuring plan to save $3 billion by ...

The multiyear effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster ...

Merck KGaA Q1 Results Rise; Cuts FY25 Outlook May 15, 2025 — 01:20 am EDT Written by RTTNews.com for RTTNews -> ...

Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% ...

Merck’s stock is falling after a rare revenue miss, and the announcement of a $3 billion cost-cutting plan that will include ...

Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove ...

Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...

By Helena Smolak Germany's Merck KGaA slashed its full-year outlook on the back of challenging macroeconomic conditions and foreign-exchange headwinds. The life-sciences and electronics company ...

Merck is undervalued with strong growth, profitability, and credit strength despite CDMO challenges, offering compelling ...

Merck & Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed ...

Photo: ralph orlowski/Reuters Germany’s Merck MRK -0.86% KGaA shares dropped after the company slashed its full-year outlook on the back of uncertainty around tariffs and foreign-exchange headwinds.